FreeTender
Accepting bidsgrantUnited States

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities

Published
31 Aug 2026
Closes
9 Nov 2026, 23:59 UTC
Value
USD 6,300,000
Reference
RFA-DK-27-112
Location
United States
Sector
Healthcare & Pharma

Details

This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from the eligible organization to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, applications will be peer-reviewed, and only meritorious applications will be considered for funding. Through this NOFO, the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites an application to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement that addresses specific knowledge gaps in the development and progression of type 1 diabetes complications. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples. Eligibility: This is a Forecast for a single source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Estimated total programme funding: USD 6300000

Expected number of awards: 1

CFDA number(s): 93.847

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 398 open Healthcare & Pharma tenders in United States. This one closes in 46 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →